+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Migraine in the United States: Key Insights into Treatment Awareness & Satisfaction

  • Report

  • 95 Pages
  • January 2024
  • Region: United States
  • Health Union
  • ID: 5944067

Exploring HCP Engagement and Migraine Treatment Experiences Among Patients

This report provides a behind-the-scenes look at the treatment experience for those living with migraine. Using detailed quantitative data, it gives a full picture of the migraine treatment story - from HCP conversations to treatment awareness to use and satisfaction - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges.

In the United States, roughly 39 million people have migraine disease.

Migraine in America 2023: Key Insights into Treatment Awareness & Satisfaction offers a glimpse into the migraine treatment experience. It includes selected insights for stakeholders seeking a more focused view of patient perspectives on migraine treatment and satisfaction. For the complete report (including additional data on quality of life and information-seeking), please see Migraine in America 2023: Understanding the Migraine Patient Experience.

This large-scale, patient-reported data leverages vital quantitative insights essential to understanding HCP treatment discussions, treatment satisfaction and awareness, clinical trial interest, and much more.

What makes this report unique?

Very simply: the focus on patients. This syndicated report is one of the few studies that is based on primary research with diagnosed patients, bringing the patient voice to the forefront.

Valuable insights. Informed decisions.

This report lifts the curtain on the patient treatment experience, giving stakeholders an actionable look at the experiences of people living with the condition. Data can be used to inform strategic decisions, including competitive assessments, landscape analyses, patient journey overlays, and forecasting inputs.

This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information.

The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including Migraine.com - to provide information, connection, and support to patients and caregivers in the U.S.

This report includes a deep-dive into:

  • HCP engagement
    • Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used
  • Migraine treatment awareness and experiences
    • Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials

Key questions answered in this report:

  • What percentage of patients see a specialist for migraine treatment?
  • What treatments have the highest aided brand awareness among patients?
  • What percentage of patients use preventive medications?
  • How many patients feel their migraine is well-controlled on their current treatment plan?
  • What percentage of patients are likely to switch or add new treatments in the next six months?
  • What medications have patients discussed with their HCP?

Methodology

Migraine in America 2023: Key Insights into Treatment Awareness & Satisfaction consists of:

  • A 20-minute online quantitative survey

Additional details:

  • Fielded: January 16, 2023 to April 14, 2023
  • Convenience sample of 4,416 respondents diagnosed with migraine
  • Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners

Table of Contents

Methodology

Respondent Demographic Highlights

Treatment Awareness and Experiences

  • Primary HCP Seen for Migraine Care
  • Aided Brand Awareness of Treatments
  • Acute Prescription Treatment Usage
  • Preventive Treatment Usage
  • Condition Control on Current Treatment
  • Clinical Trial Interest
  • Treatment Discussions with HCP

Appendix with Associated Data Charts and Distributions

Products Mentioned

Brands and treatments mentioned in this report include:

  • Oral triptan tablets or fastmelts (such as IMITREX®, MAXALT®, ZOMIG®, sumatriptan)
  • Nasal triptan spray or nasal powder (such as IMITREX®, ONZETRA™ Xsail™, Tosymra®, ZOMIG®)
  • Injection or needleless triptan injection (such as IMITREX®, ZEMBRACE™ SymTouch™)
  • Cambia® (diclofenac potassium)
  • Elyxyb™ (celecoxib) oral solution
  • FIORICET®, FIORINAL® (aspirin, butalbital, and caffeine)
  • MIGRANAL® (dihydroergotamine mesylate)
  • NURTEC® ODT (rimegepant) (used on as-needed basis to treat migraine symptoms)
  • REYVOW™ (lasmiditan)
  • TRUDHESA™ (dihydroergotamine mesylate)
  • UBRELVY™ (ubrogepant)
  • Ergot derivative other than MIGRANAL® or TRUDHESA™, such as DHE-45® (dihydroergotamine), Cafergot® (ergotamine tartrate and caffeine), Ergomar® (ergotamine tartrate tablets)
  • Anti-nausea medications, such as Zofran® (ondansetron), Compazine® (prochlorperazine), Phenergan® (promethazine)
  • Prescription analgesics (""painkillers""), such as Vicodin® (acetaminophen and hydrocodone), OxyContin® (oxycodone), Percocet® (acetaminophen and oxycodone), Dilaudid® (hydromorphone)
  • Prescription muscle relaxants, such as Robaxin® (methocarbamol), Valium® (diazepam), Flexeril® (cyclobenzaprine), ZANAFLEX® (tizanidine)
  • Prescription NSAIDs, such as Aleve® (naproxen), TORADOL® (ketorolac)
  • Cefaly® ACUTE device for acute treatment of migraine attacks
  • Nerivio® device (electronic device for acute treatment of migraine)
  • gammaCore® (non-invasive vagus nerve stimulation device)
  • AIMOVIG® (erenumab)
  • AJOVY® (fremanezumab)
  • BOTOX® (onabotulinumtoxinA) for Chronic Migraine
  • EMGALITY® (galcanezumab)
  • NURTEC® ODT (rimegepant) (taken every other day to prevent migraines or taken in advance of potential migraine triggers)
  • QULIPTA™ (atogepant)
  • Topiramate/Topiramate XR (TOPAMAX®, TROKENDI XR®, generic topiramate)
  • VYEPTI™ (eptinezumab)
  • Antiepileptic drugs other than topiramate, such as Neurontin® (gabapentin)
  • Beta blockers, such as Inderal® (propranolol), TENORMIN® (atenolol), Blocadren® (timolol)
  • Calcium channel blockers, such as CALAN® (verapamil), NORVASC® (amlodipine), flunarizine
  • Antidepressants, such as Cymbalta® (duloxetine), Elavil® (amitriptyline), Effexor® (venlafaxine)
  • Serotonergic agents, such as Sandomigran® (pizotifen), methysergide
  • Oral steroids, such as oral Solu-Medrol®, prednisone, dexamethasone
  • Lidocaine nasal drops
  • Nerve blockers or pain-blocking treatments (such as an occipital nerve block, SpringTMS®, transcranial magnetic stimulation)
  • Cefaly® PREVENT or DUAL device for migraine prevention